ASX SMALL CAPS

articles with this tag

$2.6M Capped eSense-Lab Signs US$600k Revenue Deal

$2.6M Capped eSense-Lab Signs US$600k Revenue Deal

Backed by a new leadership team, ASX-listed biotech junior, eSense-Lab (ASX:ESE) is implementing a new business model that sees it enter joint venture (JV) agreements to quickly reach multiple revenue-generating markets.

OSL’s Pancreatic Cancer Treatment Approved for Sale in Europe

OSL’s Pancreatic Cancer Treatment Approved for Sale in Europe

OncoSil Medical (ASX:OSL) has received CE Mark approval to market and sell its breakthrough implantable radiotherapy treatment for pancreatic cancer in the EU and UK.

Creso’s New Immunity Boosting CBD Hemp Teas Set for Release

Creso’s New Immunity Boosting CBD Hemp Teas Set for Release

Creso Pharma Limited (ASX: CPH) is expanding its available product line with the release of a hemp tea in Q3 2020.

ASX MedTech Junior Displays Promise for Pancreatic Cancer Patients

ASX MedTech Junior Displays Promise for Pancreatic Cancer Patients

OncoSil Medical (ASX: OSL) has developed a first-in-class, truly innovative device that treats unresectable locally advanced pancreatic cancer — that is, tumours that can’t be surgically removed.

CPH’s cannaQIX® Products Have Now Exceeded the 2.5 million Lozenges Sold Milestone

CPH’s cannaQIX® Products Have Now Exceeded the 2.5 million Lozenges Sold Milestone

Creso Pharma (ASX:CPH, FRA:1X8) has announced its second major milestone for the year. Today is has informed the market that its flagship cannaQIX® line surpassed the milestone of 100,000 packs sold. The 100,000 pack milestone corresponds to over 2.5 million cannaQIX® lozenges sold since the product’s launch in April 2018.

ANP to Rapidly Advance to Phase IIb Trial After Dosing Results Exceed Expectations

ANP to Rapidly Advance to Phase IIb Trial After Dosing Results Exceed Expectations

One ASX biotech that is making progress in DMD therapy and hoping to shake up an industry set to be worth US$4 billion by 2023 is Antisense Therapeutics (ASX:ANP).

ASX Junior Has Early Success With K9 Cancer Trials: Human Trials Await

ASX Junior Has Early Success With K9 Cancer Trials: Human Trials Await

One ASX listed clinical stage oncology company is developing novel targeted cancer therapeutics for both humans and animals.

Game Changer? ASX Stock Reverse Engineering Cannabis Plants

Game Changer? ASX Stock Reverse Engineering Cannabis Plants

Who is the ASX company with transforming qualities that could completely disrupt the cannabis and CBD markets?

Thanks for subscribing!

X